NUVB - Nuvation Bio Inc.
NYSE
->
Healthcare
->
Biotechnology
New York,
United States
Type: Equity
NUVB price evolution
NUVB
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | ||||
| Short term investments | ||||
| Net receivables | $4.25 | $4.01 | $4.28 | $3.7 |
| Inventory | ||||
| Total current assets | $564.99 | $587.17 | $608.05 | $616.43 |
| Long term investments | ||||
| Property, plant & equipment | $3.19 | $3.47 | $3.85 | $4.32 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $571.58 | $594.8 | $613.13 | $621.48 |
| Current liabilities | ||||
| Accounts payable | $12.38 | $5.21 | $2.44 | $2.21 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $59.03 | $51.09 | $15.76 | $13.97 |
| Long term debt | ||||
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $68.86 | $62.66 | $19.08 | $16.36 |
| Shareholders' equity | ||||
| Retained earnings | -$861.3 | -$820.09 | -$357.6 | -$342.8 |
| Other shareholder equity | $1.38 | -$1.27 | -$1.17 | $0.18 |
| Total shareholder equity | ||||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 31 Jan 2021 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $0.91 | |||
| Short term investments | ||||
| Net receivables | $3.7 | $2.48 | $3.04 | $1.1 |
| Inventory | ||||
| Total current assets | $616.43 | $667.32 | $772.07 | $1.25 |
| Long term investments | ||||
| Property, plant & equipment | $4.32 | $4.68 | $3.66 | $0.7 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $143.76 | |||
| Total investments | ||||
| Total assets | $621.48 | $672.14 | $776.15 | $145 |
| Current liabilities | ||||
| Accounts payable | $2.21 | $2.14 | $3.92 | $2.7 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $13.97 | $13.16 | $16.93 | $2.8 |
| Long term debt | ||||
| Total noncurrent liabilities | $137.21 | |||
| Total debt | ||||
| Total liabilities | $16.36 | $17.07 | $30.15 | $140 |
| Shareholders' equity | ||||
| Retained earnings | -$342.8 | -$267 | -$162.8 | -$18.22 |
| Other shareholder equity | $0.18 | -$5.53 | -$1.19 | $1.6 |
| Total shareholder equity | ||||
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $0.73 | $1.44 | ||
| Cost of revenue | ||||
| Gross Profit | -$0.79 | $0.09 | ||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $47.31 | $45.4 | $20.2 | $20.83 |
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | ||||
| Interest expense | $6.59 | $7 | $7.13 | $7.07 |
| Net income | ||||
| Net income | -$41.21 | -$462.49 | -$14.79 | -$13.79 |
| Income (for common shares) | ||||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 31 Jan 2021 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $99.82 | $112.33 | $3.06 | |
| Operating income | -$3.06 | |||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | ||||
| Interest expense | $24.47 | $6.22 | ||
| Net income | ||||
| Net income | -$75.8 | -$104.2 | -$18.22 | |
| Income (for common shares) | ||||
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | $70.93 | $41.81 | $7.54 | $8.92 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $1.23 | $2.77 | $0.02 | $0.63 |
| Effect of exchange rate | -$0.66 | $0.08 | ||
| Change in cash and equivalents | -$12.61 | -$8.36 | -$8.14 | -$58.45 |
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 31 Jan 2021 |
|---|---|---|---|---|
| Net income | -$18.22 | |||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | -$0.88 | |||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | $8.92 | $63.46 | -$454.67 | -$143.75 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $0.63 | $1.33 | $625.53 | $145.54 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$58.45 | -$31.32 | $102.67 | $0.91 |
News
Fundamentals
| Market cap | $1.81B |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 336.25M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$532.28M |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | -3.39 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | -$1.58 |
|---|---|
| ROA | -88.68% |
| ROE | N/A |
| Debt/Equity | N/A |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 9.57 |
| Quick ratio | N/A |